Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (231-240 of 266) with videos related to

Pageof 27
Sort By:
Cancer Immunology Research|May 12, 2018
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell CarcinomaRana R McKay, Dominick Bossé, Wanling Xie, et al.
Clinical Genitourinary Cancer|June 23, 2020
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial CarcinomaJoaquim Bellmunt Molins, Jesús García-Donas Jiménez, Begoña P Valderrama, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewMarit Ahrens, John Haanen, Laurence Albiges, et al.
The New England Journal of Medicine|October 22, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder CancerThomas Powles, Ariel G Kann, Daniel Castellano, et al.
European Urology|February 28, 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus ChemotherapyJonathan E Rosenberg, Ronac Mamtani, Guru P Sonpavde, et al.
The New England Journal of Medicine|March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaRobert J Motzer, Nizar M Tannir, David F McDermott, et al.
Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.
Cancer|July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trialRobert J Motzer, Bernard Escudier, Saby George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark TrialsJoaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
Pageof 27

Showing results (231-240 of 266) with videos related to

Sort By:
Pageof 27
Cancer Immunology Research|May 12, 2018
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell CarcinomaRana R McKay, Dominick Bossé, Wanling Xie, et al.
Clinical Genitourinary Cancer|June 23, 2020
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial CarcinomaJoaquim Bellmunt Molins, Jesús García-Donas Jiménez, Begoña P Valderrama, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewMarit Ahrens, John Haanen, Laurence Albiges, et al.
The New England Journal of Medicine|October 22, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder CancerThomas Powles, Ariel G Kann, Daniel Castellano, et al.
European Urology|February 28, 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus ChemotherapyJonathan E Rosenberg, Ronac Mamtani, Guru P Sonpavde, et al.
The New England Journal of Medicine|March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaRobert J Motzer, Nizar M Tannir, David F McDermott, et al.
Lancet (London, England)|March 9, 2016
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E Rosenberg, Jean Hoffman-Censits, Tom Powles, et al.
Cancer|July 17, 2020
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trialRobert J Motzer, Bernard Escudier, Saby George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark TrialsJoaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
Pageof 27